Intelligent Bio Solutions (INBS) Corporate presentation summary
Event summary combining transcript, slides, and related documents.
Corporate presentation summary
21 Jul, 2026Business overview and mission
Focuses on intelligent, rapid, non-invasive drug testing solutions to improve quality of life.
Aims to transform drug testing with pain-free, accessible, and cost-effective technology.
Product and technology
Offers a fingerprint-based drug screening system analyzing sweat for recent drug use.
Detects opiates, cocaine, methamphetamine, and cannabis with results in under 10 minutes.
System is portable, hygienic, and preserves sample integrity with self-locking seals.
Validation study underway for a cartridge delivering 70% faster results.
Competitive advantages
Detection window of 16–24 hours targets current impairment, not historical use.
Lower annual cost ($5,500) and faster test times compared to urine and saliva methods.
Enables in-house testing, reducing need for specialized staff and facilities.
Latest events from Intelligent Bio Solutions
- Fingertip sweat drug test offers rapid, real-time workplace screening with high margins and global growth.INBS
Planet MicroCap Las Vegas 202617 Jun 2026 - Non-invasive fingerprint drug testing drives growth, efficiency, and global market expansion.INBS
Investor presentation17 Jun 2026 - Revenue up 148% year-over-year, net loss narrowed, and cash reserves strengthened.INBS
Q4 202411 Jun 2026 - Rapid, non-invasive drug testing drives growth, innovation, and expanding global adoption.INBS
Investor presentation11 Jun 2026 - Gross margin surged as cartridge sales grew, but liquidity concerns remain without new funding.INBS
Q2 202511 Jun 2026 - Gross margin and profit surged on cartridge sales, but liquidity and funding risks persist.INBS
Q3 202511 Jun 2026 - Revenue up 10% year-over-year, but higher R&D costs widened net loss and increased risk.INBS
Q1 202511 Jun 2026 - Flexible $100M shelf registration supports growth in rapid diagnostics and US market entry.INBS
Registration filing11 Jun 2026 - Q2 revenue up 48% year-over-year, gross margin at 49%, but liquidity risks persist.INBS
Q2 202611 Jun 2026